Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 879 people in total — 219 in the placebo plus methotrexate group and 660 in the certolizumab pegol plus methotrexate group. The trial was measuring whether adding certolizumab pegol to methotrexate (a common medicine for inflammatory joint conditions) made a difference compared to adding a placebo (an inactive dummy treatment) to methotrexate. The main thing the trial was looking at was how many participants reached a sustained state of low disease activity — specifically, scoring below a certain threshold on a joint disease activity scale at both Week 40 and Week 52 of the study. The reported data shows that for the primary goal — the percentage of people who reached sustained remission (that is, a low disease activity score at both Weeks 40 and 52) — 15.0% of people in the placebo plus methotrexate group met this measure, compared with 28.9% in the certolizumab pegol plus methotrexate group. For a related secondary measure looking at a slightly broader category called "sustained low disease activity," the reported figures were 28.6% for the placebo group and 43.8% for the certolizumab pegol group. The trial also looked at joint damage using X-ray scoring. The reported data shows the average change in overall joint damage score from the start to Week 52 was 1.8 points in the placebo group and 0.2 points in the certolizumab pegol group (on a scale where higher numbers mean more damage). Additionally, 49.7% of the placebo group showed no meaningful progression of joint damage on X-ray, compared with 70.3% in the certolizumab pegol group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 27165179) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Rheumatoid Arthritis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You were diagnosed with Rheumatoid Arthritis (RA) as an adult, and your diagnosis was made less than 1 year ago
- Your blood tests show positive results for certain markers linked to RA (called Rheumatoid Factor and/or anti-CCP antibodies)
- Your RA is currently active (meaning you are experiencing symptoms)
- You have never taken any disease-modifying drugs (DMARDs) to treat RA
- You have never received any biologic treatments for RA
Who may not be able to join:
- You have been diagnosed with any other type of inflammatory joint condition
- You have a history of a joint replacement that became infected, or you have had other serious infections or significant medical conditions
- You have been diagnosed with Tuberculosis (TB), or you are considered at high risk of getting a TB infection
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: UCB Clinical Trial Call Center, +1 877 822 9493 (UCB)
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
8 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Subjects in Sustained Remission at Week 52
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.